Abstracts tagged "Pulmonary Involvement"

Abstract Number: 1931 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Aryeh Fischer³, Jerry A. Molitor⁴ and Virginia D. Steen⁵, ¹Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, ³Rheumatology / ILD Program, National Jewish Health, Denver, CO, ⁴Rheumatology, University of Minnesota, Minneapolis, MN, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Systemic sclerosis (SSc) related pulmonary hypertension (PH) carries a high mortality and patients with SSc-PH related to restrictive lung disease having an even worse…
Abstract Number: 1696 • 2014 ACR/ARHP Annual Meeting
Left Atrial Area Measurement Is Useful for Evaluating Left Ventricular Diastolic Dysfunction Coexisting with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Sumiaki Tanaka¹, Nobuhiro Sho², Tatsuo Nagai³, Yoshiyuki Arinuma² and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is a crucial organ involvement affecting survival of patients with connective tissue disease (CTDs), such as systemic sclerosis (SSc), systemic…
Abstract Number: 1692 • 2014 ACR/ARHP Annual Meeting
The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement
I.M. Markusse¹, J. Meijs², B. de Boer², A. a. Schouffoer¹, N. Ajmone Marsan³, L. J. M. Kroft⁴, M. K. Ninaber⁵, T. W. J. Huizinga² and J.K. de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Cardiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Deparment of Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pulmonology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Severe nailfold videocapillaroscopy (NVC) patterns in patients with systemic sclerosis (SSc) are associated with a high risk of organ involvement. SSc-specific autoantibodies seem to…
Abstract Number: 1441 • 2014 ACR/ARHP Annual Meeting
Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function
Torkell Ellingsen^1,2,3, Henriette Jørgensen⁴, Dino Demirovic⁴, Lone Deibjerg⁵, Frank Andersen⁵, Agnete Hedemann-Andersen⁵, Brian Bridal Løgstrup^5,6 and Suresh Rattan⁴, ¹Diagnostic Centre Region, Hospital Silkeborg Denmark, Odense, Denmark, ²The Danish National Registry DANBIO, Odense, Denmark, ³Department of Rheumatology, Odense University Hospital, Denmark, Odense, Denmark, ⁴Laboratory of Cellular Ageing, Institute of Molecular Biology and Genetics, Århus University, Århus, Denmark, ⁵Diagnostic Centre Region, Hospital Silkeborg Denmark, Silkeborg, Denmark, ⁶Cardiology, Skejby Hospital, Århus Universityhosital, Århus, Denmark
Background/Purpose: The cardiovascular comorbidity seen in early treatment naive rheumatoid arthritis (RA) can be considered as an aspect of ´´accelerated aging``. Methods: We investigated cell…
Abstract Number: 724 • 2014 ACR/ARHP Annual Meeting
Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients
Anna-Maria Hoffmann-Vold¹, Oyvind Midtvedt², Torhild Garen³, May Brit Lund⁴, T. Mogens Aalokken⁵, Jan Tore Gran² and Oyvind Molberg⁶, ¹Department of Rheumatology, Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁴Department of Respiratory Medicine, Oslo University Hospital Rikshopitalet, Oslo, Norway, ⁵Department of Radiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation in systemic sclerosis (SSc) and the leading cause of morbidity and mortality. Serial pulmonary function tests…
Abstract Number: 2707 • 2013 ACR/ARHP Annual Meeting
Downregulation Of KLF5 and Fli1 Cooperatively Contribute To Distinct Manifestations Of Systemic Sclerosis In Vitro and In Vivo
Shinji Noda¹, Yoshihide Asano¹, Katsuhito Fujiu², Ichiro Manabe², Ryozo Nagai², Kaname Akamata¹, Takashi Taniguchi¹, Takehiro Takahashi¹, Yohei Ichimura¹, Tetsuo Toyama¹, Daisuke Tsuruta³, Maria Trojanowska⁴ and Shinichi Sato¹, ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Arthritis Center, Boston University, Boston, MA
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by initial vascular injuries and resultant fibrosis of skin and certain internal organs. Although the…
Abstract Number: 695 • 2013 ACR/ARHP Annual Meeting
Combined Pulmonary Fibrosis and Emphysema (CPFE) In Systemic Sclerosis
Nicolas Champtiaux¹, Vincent Cottin², Eric Hachulla³, Dominique Valeyre⁴, Hilario Nunes⁵, David Launay⁶, Alice Berezne⁷, Bruno Crestani⁸, Loic Guillevin⁹, Jean-Francois Cordier² and Luc Mouthon¹⁰, ¹Service de Médecine Interne, hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, ²Division of Pneumology, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon 1, Lyon, France, ³Internal Medicine, Lille CEDEX, France, ⁴Department of Pneumology, Avicenne hospital (APHP), Bobigny, France, ⁵Department of Pneumology, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁷Paris Descartes University, Internal Medicine department, Cochin Hospital, Paris, France, ⁸Pneumology A, Hôpital Bichat, Paris, France, ⁹Internal Medicine, Cochin University Hospital, Paris, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis Background/Purpose: Combined pulmonary fibrosis and emphysema (CPFE) is a recently defined syndrome, in which centrilobular and/or…
Abstract Number: 2623 • 2013 ACR/ARHP Annual Meeting
A CT Evaluation Of Pulmonary and Cardiac Lesions In BEHÇET’S Syndrome Patients Without Pulmonary Symptoms
Emire Seyahi¹, Deniz Cebi Olgun², SerdaL Ugurlu¹, Idil Hanci³, Reona Takahashi⁴ and Hasan Yazici¹, ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Department of Radiology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Neurology, Krankrenhaus Nordwest, Frankfurt am Main, Frankfurt, Germany, ⁴Department of Internal Medicine, Division of Rheumatology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In Behçet’s syndrome (BS) patients with symptomatic pulmonary artery involvement (PAI) varying and multiple pulmonary parenchymal and cardiac lesions can be seen in thorax CT…
Abstract Number: 619 • 2013 ACR/ARHP Annual Meeting
Survival and Prognostic Factors In Patients With Connective Tissue Disease Associated Pulmonary Arterial Hypertension: Results From Korean Nationwide Registry
Kwi Young Kang¹, Chan Hong Jeon², Sung Jae Choi³, Seung-Ki Kwok⁴, Seong-Kyu Kim⁵, Hyoun-Ah Kim⁶, Eon Jeong Nam⁷, Yong-Beom Park⁸, Kichul Shin⁹, Jaejoon Lee¹⁰, Chang-Hoon Lee¹¹, Chan-Bum Choi¹², Shin-Seok Lee¹³ and Dae-Hyun Yoo¹⁴, ¹Rheumatology, Internal Medicine, Catholic University of Korea, Incheon St. Mary's Hospital, Seoul, South Korea, ²Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ³Rheumatology, Korea University Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ⁷Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea, ⁸Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ⁹Rheumatology, College of Medicine, Seoul National University, Seoul, South Korea, ¹⁰Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹¹Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, ¹²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ¹³Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ¹⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a major cause of mortality in connective tissue disease (CTD). We sought to quantify survival and determine factors predictive…
Abstract Number: 2610 • 2013 ACR/ARHP Annual Meeting
A New Pathogenic Role Of BAFF As a Critical Mediator Of Skin and Lung Fibrosis In Experimental Bleomycin-Induced Pulmonary Fibrosis, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis
Antoine Francois¹, Pascal Schneider², Anne Davidson³, Emmanuel Chatelus⁴, Jérôme Avouac⁵, Yannick Allanore⁶, Bérengère Villeret⁷, Aurélie Gombault⁷, Paméla Gasse⁸, Sylvain Marchand Adam⁹, Bernhard Ryffel¹⁰, Siamak Bahram¹¹, Philippe Georgel¹², Jean Sibilia¹³, Isabelle Couillin⁸ and Jacques-Eric Gottenberg¹⁴, ¹Laboratory of Physiopathology of Arthritises, University of Strasbourg, Illkirch-Strasbourg, France, ²Department of Biochemistry, University of Lausanne, Lausanne, Switzerland, ³Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁶Rheumatology, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁷Molecular Immunology and Embryology, University of Orleans and National Center for Scientific Research, Orléans, France, ⁸Molecular Immunology and Embryology, University of Orleans and National Center for Scientific Research, Orleans, France, ⁹Francois Rabelais University, National institute of the health and the medical research, Tours, France, ¹⁰UMR6218, Molecular Immunology, University and CNRS, 3b rue de la Ferollerie, Orleans, France, ¹¹Fédération of Translational Medicine of Strasbourg (FMTS), Immunorhumatology Molécular, Strasbourg, France, ¹²Université de Strasbourg, Laboratoire d'ImmunoGénétique Moléculaire Humaine, Strasbourg, France, ¹³Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁴Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Interstitial pneumonitis and lung fibrosis are frequent systemic complications of inflammatory arthritides, including systemic sclerosis (SSc), rheumatoid arthritis, or primary Sjögren’s syndrome. B lymphocytes…
Abstract Number: 2582 • 2013 ACR/ARHP Annual Meeting
Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Virginia D. Steen¹ and Robyn T. Domsic², ¹Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ²Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Trials of therapy in pulmonary hypertension(PH) have generally excluded patients with significant interstitial lung disease, but many patients with systemic sclerosis(SSc) and PH have…
Abstract Number: 2574 • 2013 ACR/ARHP Annual Meeting
Early Use of Prostacyclin Therapy Improves Transplant-Free Survival in Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension Plus Interstitial Lung Disease
Elizabeth Volkmann¹, Rajan Saggar², Bryant Torres¹, Lynne Yoder², Robert Elashoff³, Rajeev Saggar⁴, Harsh Agrawal¹, Nabeel Borazan⁵, Sarah Thomas¹ and Daniel Furst¹, ¹Medicine, University of California, Los Angeles, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Biomath, University of California, Los Angeles, Los Angeles, CA, ⁴Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ⁵Medicine, Rheumatology UCLA, Los Angeles, CA
Background/Purpose: The leading causes of death in systemic sclerosis (SSc) are pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Use of PAH therapy in…
Abstract Number: 2575 • 2013 ACR/ARHP Annual Meeting
Utility Of Autoantibody Testing For Predicting Risk Of Pulmonary Arterial Hypertension: A Retrospective Analysis In Routine Autoantibody Laboratory
Masataka Kuwana¹, Yuichiro Shirai¹, Hidekata Yasuoka¹, Tsutomu Takeuchi¹ and Kenichi Masui², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is an intractable complication of connective tissue disease (CTD). Current guidelines recommend early detection and intervention for improvement of outcomes.…
Abstract Number: 2580 • 2013 ACR/ARHP Annual Meeting
Does Mycophenolate Mofetil (MMF) Have An Effect On Pulmonary Hemodynamics? Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma (PHAROS) Cohort
Lesley Ann Saketkoo¹, Matthew R. Lammi², Jessica K. Gordon³, Paula Lauto⁴ and Virginia D. Steen⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²Section of Pulmonary and Critical Care Medicine, LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pulmonary and Critical Care Medicine, LSU Health Sciences Center, New Orleans, LA, ⁵Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Does Mycophenolate Mofetil (MMF) have an effect on Pulmonary Hemodynamics? Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) CohortBackground/Purpose: Systemic…
Abstract Number: 2585 • 2013 ACR/ARHP Annual Meeting
Left Ventricular Dysfunction Reflected By Higher Serum Brain Natriuretic Peptide Accounts For Poorer Prognosis Of Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Sumiaki Tanaka¹, Yoshiyuki Arinuma¹, Tatsuhiko Wada¹, Tatsuo Nagai², Jun Okada³ and Shunsei Hirohata¹, ¹Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Recentry, development of potent effective newer drugs for pulmonary arterial hypertension (PAH) have resulted in improving survival of the patients. However, the prognosis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].